LB PHARMACEUTICALS INC
LBRXNext catalyst
Phase 3 — LB-102
Get an email about LBRX's next catalysts
Track LB PHARMACEUTICALS (LBRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
LBRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.61 | FQ end Sep/2026 | Call: tbd
Phase 3 — LB-102
For Schizophrenia. LB Pharmaceuticals announced accelerated topline results from the Phase 3 NOVA-2 trial of LB-102 for schizophrenia are now expected in the first half of 2027, with a pre-NDA meeting with the FDA anticipated in the second half of 2027. The pivotal trial is enrolling approximately 460 patients across 25 U.S. sites.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LB-102 | Phase 2 | Schizophrenia | - | - |
Frequently asked questions
What is in LB PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in LB PHARMACEUTICALS INC's (LBRX) pipeline across Phase 2. Its lead program is LB-102 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LB PHARMACEUTICALS INC's next FDA catalyst?→
LB PHARMACEUTICALS INC's (LBRX) next tracked catalyst is a Phase 3 readout expected Jun 30, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LBRX biotech catalysts?→
Add LBRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LB PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.